CRON Strangle Strategy
CRON (Cronos Group Inc.), in the Healthcare sector, (Drug Manufacturers - Specialty & Generic industry), listed on NASDAQ.
Cronos Group Inc. operates as a cannabinoid company. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones and Happy Dance brands in the United States. The company is also involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. It sells cannabis and cannabis products, including dried cannabis, pre-rolls, edibles, concentrates, and cannabis extracts through wholesale and direct-to-client channels under its wellness platform, PEACE NATURALS; and operates under adult-use brands, Spinach. It also exports dried cannabis and cannabis oils to Germany, Israel, and Australia. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.
CRON (Cronos Group Inc.) trades in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a market capitalization of approximately $1.02B, a beta of 0.87 versus the broader market, a 52-week range of 1.84-3.43, average daily share volume of 1.5M, a public-listing history dating back to 2018, approximately 459 full-time employees. These structural characteristics shape how CRON stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.87 places CRON roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a strangle on CRON?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current CRON snapshot
As of May 15, 2026, spot at $2.62, ATM IV 43.80%, IV rank 3.78%, expected move 12.56%. The strangle on CRON below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on CRON specifically: CRON IV at 43.80% is on the cheap side of its 1-year range, which favors premium-buying structures like a CRON strangle, with a market-implied 1-standard-deviation move of approximately 12.56% (roughly $0.33 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated CRON expiries trade a higher absolute premium for lower per-day decay. Position sizing on CRON should anchor to the underlying notional of $2.62 per share and to the trader's directional view on CRON stock.
CRON strangle setup
The CRON strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With CRON near $2.62, the first option leg uses a $2.75 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed CRON chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 CRON shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $2.75 | N/A |
| Buy 1 | Put | $2.49 | N/A |
CRON strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
CRON strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on CRON. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on CRON
Strangles on CRON are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the CRON chain.
CRON thesis for this strangle
The market-implied 1-standard-deviation range for CRON extends from approximately $2.29 on the downside to $2.95 on the upside. A CRON long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current CRON IV rank near 3.78% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on CRON at 43.80%. As a Healthcare name, CRON options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to CRON-specific events.
CRON strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. CRON positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move CRON alongside the broader basket even when CRON-specific fundamentals are unchanged. Always rebuild the position from current CRON chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on CRON?
- A strangle on CRON is the strangle strategy applied to CRON (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With CRON stock trading near $2.62, the strikes shown on this page are snapped to the nearest listed CRON chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are CRON strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the CRON strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 43.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a CRON strangle?
- The breakeven for the CRON strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current CRON market-implied 1-standard-deviation expected move is approximately 12.56%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on CRON?
- Strangles on CRON are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the CRON chain.
- How does current CRON implied volatility affect this strangle?
- CRON ATM IV is at 43.80% with IV rank near 3.78%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.